Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

Peer review reports

Original Submission
24 Nov 2022	Submitted	Original manuscript
22 Feb 2023	Reviewed	Reviewer Report - Hirotaka Saikawa
24 Mar 2023	Reviewed	Reviewer Report - Kentaro Ito
16 Apr 2023	Author responded	Author comments - Qi Zhou
Resubmission - Version 2
16 Apr 2023	Submitted	Manuscript version 2
1 May 2023	Reviewed	Reviewer Report - Kentaro Ito
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
8 May 2023	Editorially accepted
14 Jun 2023	Article published	10.1186/s12890-023-02472-x

Back to article page